Hyponatremia in heart failure: The role of arginine vasopressin and its Antagonism

Congestive Heart Failure

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Rosner, Mitchell H ^a   Ronco, Claudio ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; PLACEBO; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ADRENERGIC SYSTEM; BLOOD PRESSURE; BLOOD VOLUME; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIURESIS; ELECTROLYTE BLOOD LEVEL; FLUID BALANCE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INDEX; HEART OUTPUT; HEART RATE; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; MENTAL FUNCTION; MORTALITY; NONHUMAN; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SURVIVAL; SYSTEMIC VASCULAR RESISTANCE; THIRST; URINE VOLUME; VASOCONSTRICTION; WATER ABSORPTION; WATER RETENTION; XEROSTOMIA;

EID: 77955131976     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00156.x     Document Type: Review

References (62)

1. Rosamond W, Flegal K, Furie K. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
2. Sica DA. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 2006, 73(suppl 2):S2-S7.
3. Goldberg A, Hammerman H, Petcherski S. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006, 166:781-786.
4. De Luca L, Klein L, Udelson JE. Hyponatremia in patients with heart failure. Am J Cardiol 2005, 96(suppl):19L-23L.
5. Lee CR, Watkins ML, Patterson JH. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003, 146:9-18.
6. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999, 5:357-382.
7. Sica DA. Hyponatremia and heart failure-pathophysiology and implications. Congest Heart Fail 2005, 11:274-277.
8. Ishikawa S, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 2003, 58:1-17.
9. Sharif-Naeini R, Ciura S, Zhang Z. Contribution of TRPV channels to osmosensory transduction, thirst, and vasopressin release. Kidney Int 2008, 73:811-815.
10. Dunn FL, Brennan TJ, Nelson AE. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973, 52:3212-3219.
11. Robertson GL, Athar S, Shelton RL. Osmotic control of vasopressin function. Disturbance in Body Fluid Osmolality 1977, 251-306. Robertson GL, ., Washington, DC, American Physiological Society
12. Baylis PH. Posterior pituitary function in health and disease. Clin Endocrinol Metab 1983, 12:747-770.
13. Sivukhina EV, Morozov IuE, Dolzhikov AA. Comparison of vasopressin and oxytocin expressions in the hypothalamo-neurohypophysial system of patients with chronic heart failure. Horm Metab Res 2010, 42:56-60.
14. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol 1983, 244:E72-E82.
15. Neilsen S, Kwon TH, Christensen BM. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999, 10:647-663.
16. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987, 82:1213-1219.
17. Riegger AJG, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (Lond) 1982, 62:465-469.
18. Szatalowicz VL, Arnold PE, Chaimovitz C. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981, 305:263-266.
19. Pruszczynski W, Vahanian A, Ardaillou R. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab 1984, 58:599-605.
20. Valdemarsson S, Bergdahl A, Edvinsson L. Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure. J Intern Med 1994, 235:595-601.
21. Francis GS, Benedict C, Johnstone DE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
22. Bichet DG, Kortas C, Mettauer B. Modulation of plasma and platelet vasopression by cardiac function in patients with heart failure. Kidney Int 1986, 29:1188-1196.
23. Schrier RW, Abraham W. Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
24. Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 1998, 449:415-426.
25. Lilly LS, Dzau VJ, Williams GH. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 1984, 59:924-930.
26. Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 2009, 17:10-15.
27. Tahara A, Tomura Y, Wada K. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasis and hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 1997, 30:759-766.
28. Klein L, O'Connor CM, Leimberger JD. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111:2454-2460.
29. Gheorghiade M, Gattis WA, O'Connor CM. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
30. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73:257-267.
31. Gheorghiade M, Abraham WT, Albert NM. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007, 28:980-988.
32. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005, 95(suppl):2B-7B.
33. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
34. Gheorghiade M, Rossi JS, Cotts W. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007, 167:1998-2005.
35. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
36. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
37. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002, 287:628-640.
38. Kramer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999, 106:90-96.
39. Greenberg A. Diuretic complications. Am J Med Sci 2000, 319:10-24.
40. Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992, 13(suppl G):28-33.
41. Sigurdsson A, Swedberg K. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. Eur Heart J 1995, 16(suppl N):65-72.
42. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993, 103:601-606.
43. Baglin A, Boulard JC, Hanslik T. Metabolic adverse reactions to diuretics. Drug Saf 1995, 12:161-167.
44. Abramow M, Cogan E. Clinical aspects and pathophysiology of diuretic-induced hyponatremia. Adv Nephrol Necker Hosp 1984, 13:1-28.
45. Ohnishi A, Orita Y, Takagi N. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995, 272:546-551.
46. Burrell LM, Phillips PA, Risvanis J. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 1998, 275:H176-H182. pt 2
47. Hirano T, Yamamura Y, Nokamura S. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000, 292:288-294.
48. Costello-Boerrigter LC, Smith WB, Boerrigter G. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006, 290:F273-F278.
49. Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs 2004, 5:977-983.
50. Gheorghiade M, Niazi I, Ouyang J. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial. Circulation 2003, 107:2690-2696.
51. Konstam MA, Gheorghiade M, Burnett JC. Effects of oral tolvaptan in patients hospitalized with worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
52. Gheorghiade M, Konstam MA, Burnett JC. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
53. Udelson JE, Orlandi C, Ouyang J. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52:1540-1545.
54. Abraham WT, Shamshirsaz AA, McFann K. Aquaretic effect of lixivaptan, an oral non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association Functional Class II and III chronic heart failure patients. J Am Coll Cardiol 2006, 47:1615-1621.
55. THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation. http://www.clinicaltrials.gov, Accessed 23 March 2009
56. Schrier RW, Gross P, Gheorghiade M. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
57. Udelson JE, Orlandi C, O'Brien T. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. J Am Coll Cardiol 2002, 39:156. Abstract
58. Yatsu T, Tomura Y, Tahara A. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur J Pharmacol 1997, 321:225-230.
59. Zeltser D, Rosansky S, van Rensburg H. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007, 27:447-457.
60. Udelson JE, Smith WB, Hendrix GH. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417-2423.
61. Goldsmith SR, Elkayam U, Haught WE. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008, 14:641-647.
62. Goldsmith SR, Elkayam U, McNutt B. Combined effects of conivaptan and furosemide on urine output in patients with acute decompensated heart failure. Crit Care Med 2008, 36(suppl 12):A61.